稳斑汤联合增强型体外反搏治疗冠心病PCI术后的临床疗效及对病人血栓素A_2的影响  

Clinical Efficacy of Wenban Decoction and Enhanced External Counterpulsation in the Treatment of Coronary Heart Disease after PCI and its Effect on Thromboxane A_2

作　　者：宫淑颖 宫丽鸿 Gong Shuying;Gong Lihong(Liaoning University of Traditional Chinese Medicine,Shenyang 110032,Liaoning,China)

机构地区：[1]辽宁中医药大学,沈阳110032 [2]辽宁中医药大学附属医院

出　　处：《中西医结合心脑血管病杂志》2018年第20期2929-2933,共5页Chinese Journal of Integrative Medicine on Cardio-Cerebrovascular Disease

基　　金：辽宁省重点专科能力建设项目(No.2015-370);沈阳市科技创新专项资金重点实验室建设项目(No.F14-189-1-00)

摘　　要：目的观察稳斑汤联合增强型体外反搏治疗冠心病经皮冠状动脉介入(PCI)术后的临床疗效及对病人血栓素A_2的影响。方法将60例冠心病PCI术后(痰瘀互结证)病人随机分为治疗组和对照组,各30例。对照组采用常规西药加稳斑汤治疗,治疗组在对照组基础上联合增强型体外反搏治疗,两组疗程均为4周。治疗前后根据设计研究方案与病例报告表(CRF)评定两组心绞痛症状积分、心绞痛症状疗效、中医证候积分、中医证候疗效,采用酶联免疫吸附法测两组血栓素A_2含量。结果治疗后,两组心绞痛症状积分较治疗前降低(P <0.05或P <0.01),且治疗组心绞痛症状积分显著低于对照组(P <0.01),治疗组心绞痛症状积分疗效优于对照组,差异有统计学意义(P <0.05)。治疗后,两组中医证候积分较治疗前均显著降低(P <0.01),且治疗组中医证候积分低于对照组(P <0.05),治疗组中医证候积分疗效优于对照组,差异有统计学意义(P <0.05)。治疗后,两组血栓素A_2含量较治疗前均显著降低(P <0.01),且治疗组血栓素A_2含量低于对照组(P <0.01)。两组治疗过程及治疗后均未发生肾功能损害、心力衰竭、脑出血等并发症,安全性检测指标均无异常。结论稳斑汤联合增强型体外反搏治疗能有效改善冠心病PCI术后病人的中医证候,抑制血栓素A_2的表达。Objective To observe the efficacy of Wenban decoction （WBD） and enhanced external counterpulsation （EECP） in thetreatment of coronary heart disease （CHD） after percutaneous coronary intervention （PCI） and its effect on thromboxane A2 .Method Sixty patients with CHD after PCI and phlegm and blood stasis syndrome were randomly divided into two groups：control group （ n =30） treated with routine treatment plus WBD,and treatment group （ n =30） treated with WBD and EECP in the basis of routine treat -ment for 4 weeks.Before and after treatment,according to the design study plan and case report form （CRF）, the angina symptomscores,angina symptoms efficacy,traditional Chinese medicine （TCM） syndrome scores,TCM syndrome efficacy were measured.Thecontent of thromboxane A2 in the two groups was determined by enzyme linked immunosorbent assay （ELISA）.Results After treat -ment,the scores of angina pectoris in the two groups were lower than those before treatment （ P 〈0.05 or P 〈0.01）,and anginasymptom scores in the treatment group were lower than those in the control group （ P 〈0.01）.The angina symptoms efficacy in thetreatment group was better than that in the control group （P 〈0.05）.After treatment,the scores of TCM syndromes in the two groupswere significantly lower than those before treatment （P 〈0.01）,and the scores of TCM syndromes in the treatment group were lowerthan those in the control group （P 〈0.05）.The efficacy of TCM syndrome scores in the treatment group was better than those in thecontrol group （P 〈0.05）.After treatment,the contents of thromboxane A2 in the two groups were significantly lower than those beforetreatment （P 〈0.01）,and the content of thromboxane A2 in the treatment group was lower than that in the control group （ P 〈0.01）.There was no complications such as renal dysfunction,heart failure and cerebral hemorrhage during and after treatment in two groups,and there was no abnormalities in safety test indicators. C

关 键 词：冠心病 经皮冠状动脉介入 稳斑汤 增强型体外反搏 血栓素A 心绞痛症状积分 中医证候积分 

分 类 号：R541.4[医药卫生—心血管疾病] R256.2[医药卫生—内科学]